Zymeworks Historical Income Statement

ZYME Stock

USD 14.09 0.33 2.29%

Historical analysis of Zymeworks Common income statement accounts such as Depreciation And Amortization of 18.2 M, Interest Expense of 5.8 M, Selling General Administrative of 41.6 M or Total Revenue of 78.2 M can show how well Zymeworks Common Stock performed in making a profits. Evaluating Zymeworks Common income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Zymeworks Common's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Zymeworks Common Stock latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Zymeworks Common Stock is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Zymeworks Income Statement Analysis

Zymeworks Common Stock Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Zymeworks Common shareholders. The income statement also shows Zymeworks investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Zymeworks Common Income Statement Chart

At present, Zymeworks Common's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 78.2 M, whereas Gross Profit is projected to grow to (63.6 M).

Selling General Administrative Total Revenue Other Operating Expenses Research Development Selling And Marketing Expenses

Total Revenue

Total revenue comprises all receipts Zymeworks Common Stock generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Zymeworks Common Stock. It is also known as Zymeworks Common overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Zymeworks Common's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Zymeworks Common Stock current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2021	2022	2023	2024 (projected)
Interest Expense	12.9M	3.6M	4.1M	5.8M
Depreciation And Amortization	9.6M	12.0M	17.3M	18.2M

Interest Expense Depreciation And Amortization

Zymeworks Common income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Tax Provision	Interest Income	Non Recurring	Net Interest Income	Reconciled Depreciation	Non Operating Income Net Other	Extraordinary Items	Selling And Marketing Expenses
Depreciation And Amortization		0.48	0.76	0.49	0.2	0.78	-0.39	-0.35	-0.41	0.77	-0.35	0.77	0.6	-0.33	0.9	-0.35	0.29	0.26	0.86	0.17	0.88	0.9	0.46	-0.79	-0.75
Interest Expense	0.48		0.68	0.08	0.0	0.76	-0.76	-0.77	-0.75	0.77	-0.74	0.77	0.79	-0.76	0.42	-0.77	0.02	-0.01	0.3	-0.1	0.36	0.62	0.92	-0.82	-0.1
Selling General Administrative	0.76	0.68		0.61	0.34	0.95	-0.37	-0.35	-0.38	0.91	-0.33	0.91	0.83	-0.33	0.66	-0.35	0.45	0.42	0.6	0.0	0.66	0.88	0.76	-0.91	-0.31
Total Revenue	0.49	0.08	0.61		0.89	0.62	0.45	0.46	0.44	0.62	0.49	0.61	0.63	0.48	0.24	0.46	0.89	0.88	0.18	0.03	0.21	0.48	0.17	-0.48	-0.09
Gross Profit	0.2	0.0	0.34	0.89		0.43	0.58	0.57	0.59	0.45	0.62	0.45	0.54	0.59	-0.14	0.57	0.9	0.9	-0.22	-0.11	-0.18	0.21	0.02	-0.22	0.27
Other Operating Expenses	0.78	0.76	0.95	0.62	0.43		-0.41	-0.4	-0.41	0.99	-0.37	0.99	0.93	-0.37	0.6	-0.4	0.47	0.44	0.5	-0.04	0.56	0.9	0.73	-0.94	-0.26
Operating Income	-0.39	-0.76	-0.37	0.45	0.58	-0.41		1.0	1.0	-0.41	1.0	-0.41	-0.32	1.0	-0.49	1.0	0.52	0.54	-0.46	0.02	-0.48	-0.47	-0.62	0.54	0.33
Net Income From Continuing Ops	-0.35	-0.77	-0.35	0.46	0.57	-0.4	1.0		1.0	-0.4	1.0	-0.41	-0.33	1.0	-0.44	1.0	0.51	0.53	-0.41	0.04	-0.43	-0.45	-0.62	0.53	0.27
Ebit	-0.41	-0.75	-0.38	0.44	0.59	-0.41	1.0	1.0		-0.41	1.0	-0.42	-0.32	1.0	-0.52	1.0	0.51	0.54	-0.49	0.02	-0.51	-0.49	-0.61	0.55	0.35
Research Development	0.77	0.77	0.91	0.62	0.45	0.99	-0.41	-0.4	-0.41		-0.37	1.0	0.94	-0.38	0.56	-0.4	0.47	0.44	0.45	-0.05	0.51	0.89	0.7	-0.93	-0.23
Ebitda	-0.35	-0.74	-0.33	0.49	0.62	-0.37	1.0	1.0	1.0	-0.37		-0.37	-0.28	1.0	-0.47	1.0	0.55	0.57	-0.44	0.03	-0.46	-0.44	-0.6	0.51	0.31
Cost Of Revenue	0.77	0.77	0.91	0.61	0.45	0.99	-0.41	-0.41	-0.42	1.0	-0.37		0.94	-0.38	0.56	-0.41	0.47	0.44	0.45	-0.05	0.51	0.89	0.7	-0.93	-0.23
Total Operating Expenses	0.6	0.79	0.83	0.63	0.54	0.93	-0.32	-0.33	-0.32	0.94	-0.28	0.94		-0.3	0.37	-0.33	0.53	0.5	0.25	-0.07	0.32	0.69	0.72	-0.87	-0.08
Income Before Tax	-0.33	-0.76	-0.33	0.48	0.59	-0.37	1.0	1.0	1.0	-0.38	1.0	-0.38	-0.3		-0.43	1.0	0.54	0.56	-0.4	0.03	-0.42	-0.43	-0.6	0.51	0.27
Total Other Income Expense Net	0.9	0.42	0.66	0.24	-0.14	0.6	-0.49	-0.44	-0.52	0.56	-0.47	0.56	0.37	-0.43		-0.44	0.04	0.02	0.98	0.09	0.98	0.81	0.49	-0.73	-0.87
Net Income	-0.35	-0.77	-0.35	0.46	0.57	-0.4	1.0	1.0	1.0	-0.4	1.0	-0.41	-0.33	1.0	-0.44		0.51	0.53	-0.41	0.04	-0.43	-0.45	-0.62	0.53	0.27
Income Tax Expense	0.29	0.02	0.45	0.89	0.9	0.47	0.52	0.51	0.51	0.47	0.55	0.47	0.53	0.54	0.04	0.51		1.0	-0.02	-0.03	0.01	0.3	0.11	-0.32	0.11
Tax Provision	0.26	-0.01	0.42	0.88	0.9	0.44	0.54	0.53	0.54	0.44	0.57	0.44	0.5	0.56	0.02	0.53	1.0		-0.04	-0.04	-0.01	0.28	0.09	-0.29	0.12
Interest Income	0.86	0.3	0.6	0.18	-0.22	0.5	-0.46	-0.41	-0.49	0.45	-0.44	0.45	0.25	-0.4	0.98	-0.41	-0.02	-0.04		0.19	1.0	0.74	0.39	-0.62	-0.91
Non Recurring	0.17	-0.1	0.0	0.03	-0.11	-0.04	0.02	0.04	0.02	-0.05	0.03	-0.05	-0.07	0.03	0.09	0.04	-0.03	-0.04	0.19		0.18	-0.03	-0.12	0.06	-0.28
Net Interest Income	0.88	0.36	0.66	0.21	-0.18	0.56	-0.48	-0.43	-0.51	0.51	-0.46	0.51	0.32	-0.42	0.98	-0.43	0.01	-0.01	1.0	0.18		0.77	0.43	-0.67	-0.9
Reconciled Depreciation	0.9	0.62	0.88	0.48	0.21	0.9	-0.47	-0.45	-0.49	0.89	-0.44	0.89	0.69	-0.43	0.81	-0.45	0.3	0.28	0.74	-0.03	0.77		0.6	-0.89	-0.5
Non Operating Income Net Other	0.46	0.92	0.76	0.17	0.02	0.73	-0.62	-0.62	-0.61	0.7	-0.6	0.7	0.72	-0.6	0.49	-0.62	0.11	0.09	0.39	-0.12	0.43	0.6		-0.81	-0.13
Extraordinary Items	-0.79	-0.82	-0.91	-0.48	-0.22	-0.94	0.54	0.53	0.55	-0.93	0.51	-0.93	-0.87	0.51	-0.73	0.53	-0.32	-0.29	-0.62	0.06	-0.67	-0.89	-0.81		0.41
Selling And Marketing Expenses	-0.75	-0.1	-0.31	-0.09	0.27	-0.26	0.33	0.27	0.35	-0.23	0.31	-0.23	-0.08	0.27	-0.87	0.27	0.11	0.12	-0.91	-0.28	-0.9	-0.5	-0.13	0.41

Click cells to compare fundamentals

Zymeworks Common Account Relationship Matchups

Zymeworks Common income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.5M	10.3M	9.6M	12.0M	17.3M	18.2M
Interest Expense	11.1M	17.6M	12.9M	3.6M	4.1M	5.8M
Selling General Administrative	64.2M	57.9M	42.6M	73.4M	70.4M	41.6M
Total Revenue	29.5M	39.0M	26.7M	412.5M	76.0M	78.2M
Gross Profit	(87.6M)	39.0M	26.7M	412.5M	(67.0M)	(63.6M)
Other Operating Expenses	180.1M	226.4M	242.3M	282.0M	214.1M	152.1M
Operating Income	(151.3M)	(187.5M)	(215.6M)	130.5M	(138.1M)	(131.2M)
Net Income From Continuing Ops	(145.4M)	(180.6M)	(211.8M)	124.3M	(118.7M)	(112.7M)
Ebit	(151.3M)	(187.5M)	(215.6M)	130.5M	(147.3M)	(139.9M)
Research Development	115.9M	168.5M	199.8M	208.6M	143.6M	111.0M
Ebitda	(149.8M)	(177.2M)	(206.1M)	142.5M	(130.0M)	(123.5M)
Cost Of Revenue	117.1M	170.9M	199.5M	208.7M	143.0M	110.8M
Total Operating Expenses	180.1M	226.4M	242.3M	282.0M	71.1M	136.3M
Income Before Tax	(146.0M)	(180.1M)	(212.4M)	135.2M	(119.2M)	(113.3M)
Total Other Income Expense Net	5.3M	7.3M	3.3M	4.7M	18.8M	19.8M
Net Income Applicable To Common Shares	(145.4M)	(180.6M)	(211.8M)	124.3M	111.9M	117.5M
Net Income	(145.4M)	(180.6M)	(211.8M)	124.3M	(118.7M)	(112.7M)
Income Tax Expense	(582K)	429K	(516K)	10.9M	(568K)	(539.6K)
Tax Provision	(582K)	429K	(516K)	10.9M	(568K)	(539.6K)
Interest Income	6.0M	5.7M	2.5M	3.6M	19.7M	20.7M
Net Interest Income	6.0M	5.7M	2.5M	3.6M	19.7M	20.7M
Reconciled Depreciation	7.3M	10.3M	12.2M	12.0M	17.3M	10.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:

How To Invest In Zymeworks

Details

Is Zymeworks Stock a good investment?

Details

What is Zymeworks Common's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.49)

Revenue Per Share

0.831

Quarterly Revenue Growth

(0.03)

Return On Assets

(0.15)

Return On Equity

(0.29)

The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zymeworks Historical Income Statement

About Zymeworks Income Statement Analysis

Zymeworks Common Income Statement Chart

Total Revenue

Other Operating Expenses

Zymeworks Common income statement Correlations

Zymeworks Common Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zymeworks Common income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebit	+ 1.0	Net Income From Continuing Ops

Extraordinary Items	- 0.94	Other Operating Expenses
Extraordinary Items	- 0.93	Cost Of Revenue
Extraordinary Items	- 0.93	Research Development
Selling And Marketing Expenses	- 0.91	Interest Income
Extraordinary Items	- 0.91	Selling General Administrative
Selling And Marketing Expenses	- 0.9	Net Interest Income